vs
AbCellera Biologics Inc.（ABCL）与HARTE HANKS INC（HHS）财务数据对比。点击上方公司名可切换其他公司
AbCellera Biologics Inc.的季度营收约是HARTE HANKS INC的1.1倍（$44.9M vs $39.9M），HARTE HANKS INC净利率更高（5.5% vs -19.9%，领先25.5%），AbCellera Biologics Inc.同比增速更快（788.4% vs -15.4%），HARTE HANKS INC自由现金流更多（$-686.0K vs $-44.6M），过去两年AbCellera Biologics Inc.的营收复合增速更高（112.3% vs -6.4%）
AbCellera Biologics是一家总部位于不列颠哥伦比亚省温哥华的生物科技企业，核心业务是探索与开发抗体治疗药物。该公司凭借 proprietary 技术平台可在60天内开发出医疗应对方案，其单细胞筛选技术平台最早诞生于不列颠哥伦比亚大学，还曾作为核心力量参与美国国防高级研究计划局的大流行预防平台项目。
哈特·汉克斯是一家总部位于美国马萨诸塞州波士顿的全球营销服务企业，主营业务涵盖数据分析、营销战略规划、营销技术支持、创意服务、数字营销、客户服务、直邮服务以及物流履约等多个领域，为全球客户提供全方位的营销解决方案。
ABCL vs HHS — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $44.9M | $39.9M |
| 净利润 | $-8.9M | $2.2M |
| 毛利率 | — | — |
| 营业利润率 | -63.7% | -0.3% |
| 净利率 | -19.9% | 5.5% |
| 营收同比 | 788.4% | -15.4% |
| 净利润同比 | 73.9% | — |
| 每股收益（稀释后） | $-0.03 | $0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $44.9M | $39.9M | ||
| Q3 25 | $9.0M | $39.5M | ||
| Q2 25 | $17.1M | $38.6M | ||
| Q1 25 | $4.2M | $41.6M | ||
| Q4 24 | $5.0M | $47.1M | ||
| Q3 24 | $6.5M | $47.6M | ||
| Q2 24 | $7.3M | $45.0M | ||
| Q1 24 | $10.0M | $45.4M |
| Q4 25 | $-8.9M | $2.2M | ||
| Q3 25 | $-57.1M | $-2.3M | ||
| Q2 25 | $-34.7M | $-335.0K | ||
| Q1 25 | $-45.6M | $-392.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-51.1M | $142.0K | ||
| Q2 24 | $-36.9M | $-27.8M | ||
| Q1 24 | $-40.6M | $-171.0K |
| Q4 25 | -63.7% | -0.3% | ||
| Q3 25 | -851.8% | 1.3% | ||
| Q2 25 | -290.2% | 0.1% | ||
| Q1 25 | -1479.6% | -0.1% | ||
| Q4 24 | — | -3.3% | ||
| Q3 24 | -1439.4% | 4.0% | ||
| Q2 24 | -1276.2% | 3.0% | ||
| Q1 24 | -551.5% | 0.8% |
| Q4 25 | -19.9% | 5.5% | ||
| Q3 25 | -637.8% | -5.8% | ||
| Q2 25 | -203.3% | -0.9% | ||
| Q1 25 | -1077.2% | -0.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -785.4% | 0.3% | ||
| Q2 24 | -504.3% | -61.8% | ||
| Q1 24 | -408.0% | -0.4% |
| Q4 25 | $-0.03 | $0.30 | ||
| Q3 25 | $-0.19 | $-0.31 | ||
| Q2 25 | $-0.12 | $-0.05 | ||
| Q1 25 | $-0.15 | $-0.05 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | $-0.17 | $0.02 | ||
| Q2 24 | $-0.13 | $-3.84 | ||
| Q1 24 | $-0.14 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $128.5M | $5.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $966.9M | $20.5M |
| 总资产 | $1.4B | $91.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $128.5M | $5.6M | ||
| Q3 25 | $83.2M | $6.5M | ||
| Q2 25 | $92.4M | $4.8M | ||
| Q1 25 | $159.3M | $9.0M | ||
| Q4 24 | $156.3M | $9.8M | ||
| Q3 24 | $126.6M | $5.9M | ||
| Q2 24 | $148.3M | $11.0M | ||
| Q1 24 | $123.6M | $11.5M |
| Q4 25 | $966.9M | $20.5M | ||
| Q3 25 | $964.0M | $19.9M | ||
| Q2 25 | $1.0B | $22.2M | ||
| Q1 25 | $1.0B | $21.4M | ||
| Q4 24 | $1.1B | $21.7M | ||
| Q3 24 | $1.1B | $21.0M | ||
| Q2 24 | $1.1B | $20.6M | ||
| Q1 24 | $1.1B | $20.0M |
| Q4 25 | $1.4B | $91.8M | ||
| Q3 25 | $1.4B | $92.7M | ||
| Q2 25 | $1.4B | $95.0M | ||
| Q1 25 | $1.3B | $100.6M | ||
| Q4 24 | $1.4B | $101.8M | ||
| Q3 24 | $1.4B | $108.1M | ||
| Q2 24 | $1.4B | $109.7M | ||
| Q1 24 | $1.5B | $113.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-34.7M | $737.0K |
| 自由现金流经营现金流 - 资本支出 | $-44.6M | $-686.0K |
| 自由现金流率自由现金流/营收 | -99.4% | -1.7% |
| 资本支出强度资本支出/营收 | 21.9% | 3.6% |
| 现金转化率经营现金流/净利润 | — | 0.33× |
| 过去12个月自由现金流最近4个季度 | $-174.1M | $-4.5M |
8季度趋势，按日历期对齐
| Q4 25 | $-34.7M | $737.0K | ||
| Q3 25 | $-52.6M | $3.2M | ||
| Q2 25 | $-32.4M | $-4.8M | ||
| Q1 25 | $-11.6M | $-818.0K | ||
| Q4 24 | $-108.6M | $4.0M | ||
| Q3 24 | $-28.9M | $-2.9M | ||
| Q2 24 | $-30.0M | $1.6M | ||
| Q1 24 | $-41.7M | $-5.7M |
| Q4 25 | $-44.6M | $-686.0K | ||
| Q3 25 | $-61.5M | $2.2M | ||
| Q2 25 | $-45.8M | $-5.1M | ||
| Q1 25 | $-22.2M | $-923.0K | ||
| Q4 24 | $-187.0M | $3.4M | ||
| Q3 24 | $-47.4M | $-4.9M | ||
| Q2 24 | $-50.1M | $926.0K | ||
| Q1 24 | $-65.8M | $-6.2M |
| Q4 25 | -99.4% | -1.7% | ||
| Q3 25 | -687.0% | 5.5% | ||
| Q2 25 | -267.9% | -13.1% | ||
| Q1 25 | -524.0% | -2.2% | ||
| Q4 24 | -3702.8% | 7.3% | ||
| Q3 24 | -728.4% | -10.2% | ||
| Q2 24 | -683.8% | 2.1% | ||
| Q1 24 | -661.5% | -13.7% |
| Q4 25 | 21.9% | 3.6% | ||
| Q3 25 | 99.7% | 2.5% | ||
| Q2 25 | 78.2% | 0.6% | ||
| Q1 25 | 251.1% | 0.3% | ||
| Q4 24 | 1552.7% | 1.3% | ||
| Q3 24 | 284.6% | 4.0% | ||
| Q2 24 | 274.6% | 1.5% | ||
| Q1 24 | 242.5% | 1.2% |
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -20.76× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABCL
暂无分部数据
HHS
| Fulfillment And Logistics Services | $17.3M | 43% |
| Customer Care | $13.7M | 34% |
| Other | $8.9M | 22% |
